K. Marschke

A. Hogue, E. Vajda, William Y. Chang, 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Selective androgen receptor modulators based on a series of 7H-[1,4]oxazino[3,2-g]quinolin-7-ones with improved in vivo activity.

Min Wu, William Y. Chang, D. Karanewsky, 2008, Bioorganic & medicinal chemistry letters.

Substituted 6-(1-pyrrolidine)quinolin-2(1H)-ones as novel selective androgen receptor modulators.

P. Rix, E. Vajda, O. H. Viveros, 2007, Journal of medicinal chemistry.

Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one.

J. Edwards, L. Hamann, M. Goldman, 1999, Bioorganic & medicinal chemistry letters.

New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone.

J. Edwards, T. K. Jones, K. Marschke, 1998, Bioorganic & medicinal chemistry letters.

Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.

J. Edwards, L. Hamann, T. K. Jones, 1998, Journal of medicinal chemistry.

Novel series of potent, nonsteroidal, selective androgen receptor modulators based on 7H-[1,4]oxazino[3,2-g]quinolin-7-ones.

Dale E Mais, James P Edwards, J. Edwards, 2007, Journal of medicinal chemistry.

Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.

William Y. Chang, A. Negro-Vilar, A. Kallel, 2007, Bioorganic & medicinal chemistry letters.

5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists.

M. Gottardis, E. Kallel, T. K. Jones, 1998, Journal of medicinal chemistry.

Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.

Min Wu, B. Pio, A. Negro-Vilar, 2007, Bioorganic & medicinal chemistry letters.

An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate.

Russell Turner, William Schrader, R. Turner, 2007, Endocrinology.

Discovery of 6-N,N-bis(2,2,2-trifluoroethyl)amino- 4-trifluoromethylquinolin-2(1H)-one as a novel selective androgen receptor modulator.

Arjan van Oeveren, Mehrnouch Motamedi, Neelakandha S Mani, 2006, Journal of medicinal chemistry.

5-Alkyl 1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal progesterone receptor modulators.

J. Edwards, M. Gottardis, T. K. Jones, 1998, Bioorganic & medicinal chemistry letters.

Synthesis and biological activity of 5-methylidene 1,2-dihydrochromeno[3,4-f]quinoline derivatives as progesterone receptor modulators.

J. Edwards, B. Pio, T. K. Jones, 2003, Bioorganic & medicinal chemistry letters.

Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines.

J. Edwards, L. Hamann, T. K. Jones, 2000, Bioorganic & medicinal chemistry letters.

Nonsteroidal 2,3-dihydroquinoline glucocorticoid receptor agonists with reduced PEPCK activation.

Steven L. Roach, Lino J Valdez, D. Rungta, 2011, Bioorganic & medicinal chemistry letters.

A tissue-selective nonsteroidal progesterone receptor modulator: 7,9-difluoro-5-(3-methylcyclohex-2-enyl)-2,2,4-trimethyl-1,2-dihydrochromeno[3,4-f]quinoline.

M. Groen, D. Mais, P. Verbost, 2008, Journal of medicinal chemistry.

Synthesis and characterization of nonsteroidal glucocorticoid receptor modulators for multiple myeloma.

Dale E Mais, W. Lamph, E. Kallel, 2007, Journal of medicinal chemistry.

Discovery and preliminary SAR studies of a novel, nonsteroidal progesterone receptor antagonist pharmacophore.

J. Edwards, M. Goldman, T. K. Jones, 1998, Journal of medicinal chemistry.

6-Aryl-1,4-dihydro-benzo[d][1,3]oxazin- 2-ones: a novel class of potent, selective, and orally active nonsteroidal progesterone receptor antagonists.

R. Winneker, S. Lundeen, Eugene A. Terefenko, 2002, Journal of medicinal chemistry.

4-Alkyl- and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: potent, nonsteroidal androgen receptor agonists.

J. Edwards, L. Hamann, T. K. Jones, 1999, Bioorganic & medicinal chemistry letters.

Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone.

L Zhi, C M Tegley, K B Marschke, 1999, Bioorganic & medicinal chemistry letters.

5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines as potent, orally active, nonsteroidal progesterone receptor agonists: the effect of D-ring substituents.

J. Edwards, M. Gottardis, T. K. Jones, 1998, Journal of Medicinal Chemistry.

5(Z)-benzylidene-1,2-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5H-1-aza-6-oxa-chrysenes as non-steroidal glucocorticoid receptor modulators.

Steven L. Roach, J. Miner, A. Negro-Vilar, 2007, Bioorganic & medicinal chemistry letters.

Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore.

J. Edwards, B. Pio, T. K. Jones, 2003, Bioorganic & medicinal chemistry letters.

5-Aryl-1,2,3,4-tetrahydrochromeno[3,4-f]quinolin-3-ones as a novel class of nonsteroidal progesterone receptor agonists: effect of A-ring modification.

T. K. Jones, D. Mais, C. Tegley, 1999, Journal of medicinal chemistry.

5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists.

M. Gottardis, T. K. Jones, C. Tegley, 1998, Journal of medicinal chemistry.

Nonsteroidal progesterone receptor antagonists based on a conformationally-restricted subseries of 6-aryl-1,2-dihydro-2,2,4-trimethylquinolines.

J. Edwards, L. Hamann, M. Goldman, 1998, Bioorganic & medicinal chemistry letters.

Structure—Activity Relationships and Sub‐Type Selectivity in an Oxabicyclic Estrogen Receptor α/β Agonist Scaffold.

L. Hamann, D. Karanewsky, E. Allegretto, 2005 .

Structure–activity relationships and sub-type selectivity in an oxabicyclic estrogen receptor α/β agonist scaffold

L. Hamann, D. Karanewsky, E. Allegretto, 2005 .

Estrogen and androgen receptors in the liver of cynomolgus monkeys (Macaca fascicularis).

D. Koritnik, K. Marschke, 1987, Journal of steroid biochemistry.

Androgen receptor defects : Historical, clinical, and molecular perspectives

F. S. French, E. Wilson, C. Quigley, 1995 .

Estrogen Receptor β Activates the Human Retinoic Acid Receptorα -1 Promoter in Response to Tamoxifen and Other Estrogen Receptor Antagonists, but Not in Response to Estrogen

D. Mais, A. Zou, E. Allegretto, 1999 .

Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study

J. Rosenstock, D. D’Alessio, J. Frias, 2019, Diabetes Care.

Ef ﬁ cacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study

J. Rosenstock, J. Frias, J. Pettus, 2019 .

Estrogen and estrogen receptor antagonists stimulate transcription from the human retinoic acid receptor-alpha 1 promoter via a novel sequence.

M. Elgort, A. Zou, E. Allegretto, 1996, Molecular endocrinology.

Synthesis and progesterone receptor antagonist activities of 6-aryl benzimidazolones and benzothiazolones.

Z. Zhang, P. Zhang, Eugene A. Terefenko, 2001, Bioorganic & medicinal chemistry letters.

Nonsteroidal progesterone receptor antagonists based on 6-thiophenehydroquinolines.

B. Pio, T. K. Jones, D. Mais, 2000, Bioorganic & medicinal chemistry letters.

Biological characterization of a heterodimer-selective retinoid X receptor modulator: potential benefits for the treatment of type 2 diabetes.

M. D. Leibowitz, K. Ogilvie, M. Faul, 2006, Endocrinology.

Discovery of orally available tetrahydroquinoline-based glucocorticoid receptor agonists.

Steven L. Roach, J. Miner, D. Mais, 2011, Bioorganic & medicinal chemistry letters.

Tetrahydroquinoline glucocorticoid receptor agonists: discovery of a 3-hydroxyl for improving receptor selectivity.

Steven L. Roach, J. Miner, D. Mais, 2011, Bioorganic & medicinal chemistry letters.

Novel class of non-steroidal progesterone receptor antagonists

K. Marschke, L. Zhi, 1999 .

Characterization of mutant androgen receptors causing partial androgen insensitivity syndrome.

F. S. French, E. Wilson, Eric P. Smith, 1994, The Journal of clinical endocrinology and metabolism.

Identification of polymorphisms associated with hypertriglyceridemia and prolonged survival induced by bexarotene in treating non-small cell lung cancer.

Matthew A. Zapala, N. Schork, N. Malo, 2011, Anticancer research.

A Non-Steroidal, Glucocorticoid Receptor Antagonist

M. Nakane, J. Rosen, J. Miner, 2003, Molecular endocrinology.

Specificity of simple hormone response elements in androgen regulated genes

F. S. French, Jiann-an Tan, K. Marschke, 1995, Endocrine.